Accrued Liabilities, Current in USD of BIOCEPT INC from Q4 2013 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
BIOCEPT INC quarterly Accrued Liabilities, Current history and change rate from Q4 2013 to Q2 2023.
  • BIOCEPT INC Accrued Liabilities, Current for the quarter ending 30 Jun 2023 was $1,529,000, a 44% decline year-over-year.
Source SEC data
View on sec.gov
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Change (%)

BIOCEPT INC Quarterly Accrued Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $1,529,000 -$1,208,000 -44% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $1,300,000 -$3,250,000 -71% 31 Mar 2023 10-Q 10 May 2023 2023 Q1
Q4 2022 $2,249,000 -$769,000 -25% 31 Dec 2022 10-Q 14 Aug 2023 2023 Q2
Q3 2022 $2,177,000 -$407,015 -16% 30 Sep 2022 10-Q/A 17 Apr 2023 2022 Q3
Q2 2022 $2,737,000 +$326,061 +14% 30 Jun 2022 10-Q 10 Nov 2022 2022 Q2
Q1 2022 $4,550,000 +$1,112,425 +32% 31 Mar 2022 10-Q 23 May 2022 2022 Q1
Q4 2021 $3,018,000 -$148,000 -4.7% 31 Dec 2021 10-K 17 Apr 2023 2022 FY
Q3 2021 $2,584,015 -$38,707 -1.5% 30 Sep 2021 10-Q/A 15 Feb 2022 2021 Q3
Q2 2021 $2,410,939 +$539,141 +29% 30 Jun 2021 10-Q 16 Aug 2021 2021 Q2
Q1 2021 $3,437,575 +$1,071,587 +45% 31 Mar 2021 10-Q 12 May 2021 2021 Q1
Q4 2020 $3,166,000 +$1,185,796 +60% 31 Dec 2020 10-K 05 Apr 2022 2021 FY
Q3 2020 $2,622,722 +$775,738 +42% 30 Sep 2020 10-Q 16 Nov 2020 2020 Q3
Q2 2020 $1,871,798 +$380,990 +26% 30 Jun 2020 10-Q 13 Aug 2020 2020 Q2
Q1 2020 $2,365,988 +$228,192 +11% 31 Mar 2020 10-Q 14 May 2020 2020 Q1
Q4 2019 $1,980,204 +$51,811 +2.7% 31 Dec 2019 10-K 31 Mar 2021 2020 FY
Q3 2019 $1,846,984 -$106,986 -5.5% 30 Sep 2019 10-Q 13 Nov 2019 2019 Q3
Q2 2019 $1,490,808 -$27,429 -1.8% 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 $2,137,796 -$133,473 -5.9% 31 Mar 2019 10-Q 14 May 2019 2019 Q1
Q4 2018 $1,928,393 +$176,030 +10% 31 Dec 2018 10-K 27 Mar 2020 2019 FY
Q3 2018 $1,953,970 -$220,415 -10% 30 Sep 2018 10-Q 14 Nov 2018 2018 Q3
Q2 2018 $1,518,237 +$130,470 +9.4% 30 Jun 2018 10-Q 14 Aug 2018 2018 Q2
Q1 2018 $2,271,269 +$622,810 +38% 31 Mar 2018 10-Q 15 May 2018 2018 Q1
Q4 2017 $1,752,363 +$592,327 +51% 31 Dec 2017 10-K 29 Mar 2019 2018 FY
Q3 2017 $2,174,385 +$1,030,522 +90% 30 Sep 2017 10-Q 14 Nov 2017 2017 Q3
Q2 2017 $1,387,767 +$569,989 +70% 30 Jun 2017 10-Q 14 Aug 2017 2017 Q2
Q1 2017 $1,648,459 +$465,598 +39% 31 Mar 2017 10-Q 15 May 2017 2017 Q1
Q4 2016 $1,160,036 +$193,137 +20% 31 Dec 2016 10-K 28 Mar 2018 2017 FY
Q3 2016 $1,143,863 +$227,133 +25% 30 Sep 2016 10-Q 10 Nov 2016 2016 Q3
Q2 2016 $817,778 -$66,801 -7.6% 30 Jun 2016 10-Q 05 Aug 2016 2016 Q2
Q1 2016 $1,182,861 +$301,819 +34% 31 Mar 2016 10-Q 13 May 2016 2016 Q1
Q4 2015 $966,899 +$266,996 +38% 31 Dec 2015 10-K 28 Mar 2017 2016 FY
Q3 2015 $916,730 +$336,128 +58% 30 Sep 2015 10-Q 09 Nov 2015 2015 Q3
Q2 2015 $884,579 +$388,258 +78% 30 Jun 2015 10-Q 11 Aug 2015 2015 Q2
Q1 2015 $881,042 +$400,483 +83% 31 Mar 2015 10-Q 13 May 2015 2015 Q1
Q4 2014 $699,903 -$1,542,155 -69% 31 Dec 2014 10-K 10 Mar 2016 2015 FY
Q3 2014 $580,602 30 Sep 2014 10-Q 14 Nov 2014 2014 Q3
Q2 2014 $496,321 30 Jun 2014 10-Q 08 Aug 2014 2014 Q2
Q1 2014 $480,559 31 Mar 2014 10-Q 14 May 2014 2014 Q1
Q4 2013 $2,242,058 31 Dec 2013 10-K 11 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.